lilly oral glp-1 Eli Lilly's for type 2 diabetes submission in the U.S Eli Lilly Gets Speedy FDA
Description
Limited preclinical and clinical data suggest that GLP-1 receptor agonists might modestly influence cortisol metabolism or HPA axis function in certain contexts, but findings have been inconsistent and not practice-changing
The interaction between PARP-1 and LXR was verified, and the effects of PARP-1 on LXR-mediated ABCA1 expression were determined
Medication Review: Discuss with your doctor if you're on other diabetes medications, as dosage adjustments might be necessary to prevent hypoglycemia
( A ) Pre-treatment body weight in control and Liv Fgf21/ mice (One-way ANOVA: F (3, 27) = 0.1226, P = 0.9460)
